Aventis Pharma expects to launch a prostate
cancer drug Cabazitaxel by next year for which it is currently in the process
of getting approval from the drug regulator DCGI.
The company also has 15 to 20 molecules in the pipeline. 0ut of them half are in the third stage of development and these could be for therapeutic areas like diabetes, thrombosis and other types of cancer besides cardiovascular diseases.
The company also has 15 to 20 molecules in the pipeline. 0ut of them half are in the third stage of development and these could be for therapeutic areas like diabetes, thrombosis and other types of cancer besides cardiovascular diseases.
No comments:
Post a Comment